RxDoctor Payments DataLook up a doctor →

Rajiv Dua, MD

Family Medicine · Columbia, MDNPI 1043326945

Payments from drug & device makers

$765,259in general payments, 2019–2025

Across 388 payments — averaging $1972.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$352K
  • Genentech, Inc.$175K
  • F. Hoffmann-la Roche AG$68K
  • Eli Lilly$53K
  • Seqirus USA Inc$33K
  • GSK$29K
  • plus $56K from 42 others
$15,373in research payments, 2019–2025

Across 1 payment — averaging $15,373 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$15K

What the payments were for

  • Travel & lodging$2,16131%
  • Food & beverage$4,69868%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$765,259 in reported general payments places this provider in the 95th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$430,329
Medicare patients
1,569
Services billed
9,200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide76$94,672
EliquisApixaban52$61,547
JardianceEmpagliflozin23$30,947
Tresiba Flextouch U-200Insulin Degludec17$21,109
FarxigaDapagliflozin Propanediol14$20,435
XareltoRivaroxaban15$19,405
MounjaroTirzepatide17$18,211
Levemir FlexpenInsulin Detemir11$6,225
GemtesaVibegron11$5,629
Atorvastatin Calcium298$4,331
Rosuvastatin Calcium132$2,347
Amlodipine Besylate219$1,858
SynthroidLevothyroxine Sodium28$1,834
Metoprolol Succinate100$1,775
Tamsulosin Hcl95$1,668

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$819$94,67276 claims
PfizerEliquis$16,163$61,54752 claims
Boehringer IngelheimJardiance$110$30,94723 claims
AstraZenecaFarxiga$7,936$20,43514 claims
Johnson & JohnsonXarelto$79$19,40515 claims
Lilly USA, LLCMounjaro$261$18,21117 claims
Sumitomo Pharma America, Inc.Gemtesa$73$5,62911 claims
AbbVieSynthroid$414$1,83428 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Columbia

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →